JP6754353B2 - ハンチントンタンパク質のイメージング用プローブ - Google Patents

ハンチントンタンパク質のイメージング用プローブ Download PDF

Info

Publication number
JP6754353B2
JP6754353B2 JP2017511926A JP2017511926A JP6754353B2 JP 6754353 B2 JP6754353 B2 JP 6754353B2 JP 2017511926 A JP2017511926 A JP 2017511926A JP 2017511926 A JP2017511926 A JP 2017511926A JP 6754353 B2 JP6754353 B2 JP 6754353B2
Authority
JP
Japan
Prior art keywords
pyridine
methoxy
carbonitrile
benzofuran
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017511926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529340A (ja
JP2017529340A5 (https=
Inventor
ドミンゲス,セリア
ウィチャック,ジョン
バード,ジョナサン
キセリョーフ,アレックス
ブラウン,クリストファー,ジョン
プライム,マイケル,エドワード
ジョンソン,ピーター,デーヴィッド
クラーク−フルー,ダニエル
Original Assignee
シーエイチディーアイ ファウンデーション,インコーポレーテッド
シーエイチディーアイ ファウンデーション,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエイチディーアイ ファウンデーション,インコーポレーテッド, シーエイチディーアイ ファウンデーション,インコーポレーテッド filed Critical シーエイチディーアイ ファウンデーション,インコーポレーテッド
Publication of JP2017529340A publication Critical patent/JP2017529340A/ja
Publication of JP2017529340A5 publication Critical patent/JP2017529340A5/ja
Application granted granted Critical
Publication of JP6754353B2 publication Critical patent/JP6754353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017511926A 2014-08-29 2015-08-28 ハンチントンタンパク質のイメージング用プローブ Active JP6754353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043590P 2014-08-29 2014-08-29
US62/043,590 2014-08-29
PCT/US2015/047401 WO2016033440A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (3)

Publication Number Publication Date
JP2017529340A JP2017529340A (ja) 2017-10-05
JP2017529340A5 JP2017529340A5 (https=) 2018-10-11
JP6754353B2 true JP6754353B2 (ja) 2020-09-09

Family

ID=55400645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511926A Active JP6754353B2 (ja) 2014-08-29 2015-08-28 ハンチントンタンパク質のイメージング用プローブ

Country Status (20)

Country Link
US (2) US11104691B2 (https=)
EP (1) EP3197277B1 (https=)
JP (1) JP6754353B2 (https=)
KR (1) KR102410733B1 (https=)
CN (1) CN107105667B (https=)
AU (2) AU2015308769A1 (https=)
BR (1) BR112017004140B1 (https=)
CA (1) CA2959533C (https=)
DK (1) DK3197277T3 (https=)
EA (1) EA039923B1 (https=)
ES (1) ES2905095T3 (https=)
HR (1) HRP20220001T1 (https=)
HU (1) HUE057702T2 (https=)
IL (1) IL250802B (https=)
MX (1) MX386798B (https=)
PL (1) PL3197277T3 (https=)
PT (1) PT3197277T (https=)
SG (1) SG11201701592SA (https=)
SI (1) SI3197277T1 (https=)
WO (1) WO2016033440A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035646B1 (ru) 2014-08-29 2020-07-21 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
SI3186241T1 (sl) 2014-08-29 2021-03-31 Chdi Foundation, Inc. Sonde za slikanje Huntingtonovega proteina
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CN107105667B (zh) 2014-08-29 2021-08-17 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
MX382156B (es) 2015-08-28 2025-03-13 Chdi Foundation Inc Sondas para formar imagenes de proteina de huntingtina.
WO2019075402A1 (en) * 2017-10-12 2019-04-18 University Of Kansas METHODS FOR TREATING GASTROINTESTINAL SYNDROME INDUCED BY RADIATION
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
MX2021013574A (es) 2019-05-09 2021-12-10 Hoffmann La Roche Sintesis de imidazo[1,2-a]pirimidinas etiquetadas.
CN114773312B (zh) * 2021-10-29 2024-03-26 北京鑫诺康桥药物研究有限公司 一种盐酸阿罗洛尔中间体的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
CA2500358A1 (en) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles
WO2007148755A1 (ja) * 2006-06-21 2007-12-27 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US20090252680A1 (en) * 2006-11-17 2009-10-08 Nihon- Medi-Physics Co., Ltd Novel compound with affinity for amyloid
CA2670436A1 (en) * 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
WO2008091195A1 (en) 2007-01-22 2008-07-31 Astrazeneca Ab Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives
EP2216052A4 (en) 2007-10-30 2012-11-21 Nihon Mediphysics Co Ltd USE OF A NEW COMPOUND WITH AFFINITY FOR AMYLOID AND METHOD FOR THE PRODUCTION THEREOF
FR2928923B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
JP2011529086A (ja) * 2008-07-24 2011-12-01 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Ad病変を同定するために有用な造影剤
CA2737028C (en) * 2008-09-23 2017-06-27 Wista Laboratories Ltd. Ligands for aggregated tau molecules
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
AU2012259929B2 (en) * 2011-05-20 2016-08-04 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
CA2839199C (en) * 2011-06-24 2018-11-06 Nihon Medi-Physics Co., Ltd. Novel compound with amyloid affinity
JP2013237655A (ja) * 2012-05-17 2013-11-28 Kyoto Univ コンフォメーション病診断用分子プローブ
WO2014076021A1 (en) * 2012-11-14 2014-05-22 F. Hoffmann-La Roche Ag Imidazopyridine derivatives
RU2675818C2 (ru) 2013-03-14 2018-12-25 Галапаго Нв Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств
CA2920068A1 (en) * 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools
SI3186241T1 (sl) 2014-08-29 2021-03-31 Chdi Foundation, Inc. Sonde za slikanje Huntingtonovega proteina
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EA035646B1 (ru) 2014-08-29 2020-07-21 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
CN107105667B (zh) 2014-08-29 2021-08-17 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
MX382156B (es) 2015-08-28 2025-03-13 Chdi Foundation Inc Sondas para formar imagenes de proteina de huntingtina.

Also Published As

Publication number Publication date
PT3197277T (pt) 2022-02-01
DK3197277T3 (da) 2022-01-31
JP2017529340A (ja) 2017-10-05
AU2019283999A1 (en) 2020-01-23
EA201790400A1 (ru) 2017-09-29
CN107105667A (zh) 2017-08-29
KR20170047303A (ko) 2017-05-04
KR102410733B1 (ko) 2022-06-20
PL3197277T3 (pl) 2022-04-04
SI3197277T1 (sl) 2022-04-29
WO2016033440A1 (en) 2016-03-03
EP3197277A4 (en) 2018-04-18
US20170283439A1 (en) 2017-10-05
EA039923B1 (ru) 2022-03-28
AU2015308769A1 (en) 2017-03-23
MX386798B (es) 2025-03-19
EP3197277A1 (en) 2017-08-02
HRP20220001T1 (hr) 2022-04-01
IL250802A0 (en) 2017-04-30
SG11201701592SA (en) 2017-03-30
US11104691B2 (en) 2021-08-31
CA2959533C (en) 2023-03-07
IL250802B (en) 2020-08-31
CA2959533A1 (en) 2016-03-03
AU2019283999B2 (en) 2021-07-22
BR112017004140A2 (pt) 2017-12-12
HUE057702T2 (hu) 2022-05-28
US11851446B2 (en) 2023-12-26
MX2017002702A (es) 2017-10-23
ES2905095T3 (es) 2022-04-07
US20210380608A1 (en) 2021-12-09
CN107105667B (zh) 2021-08-17
BR112017004140B1 (pt) 2023-01-10
EP3197277B1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
JP7126541B2 (ja) ハンチントンタンパク質のイメージング用プローブ
JP6754353B2 (ja) ハンチントンタンパク質のイメージング用プローブ
JP7042940B2 (ja) ハンチントンタンパク質のイメージング用プローブ
JP6944929B2 (ja) ハンチントンタンパク質のイメージング用プローブ
US10907197B2 (en) Probes for imaging huntingtin protein
HK40110855A (zh) 用於成像亨廷顿蛋白的探针

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200821

R150 Certificate of patent or registration of utility model

Ref document number: 6754353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250